ATXS — Astria Therapeutics, Inc.

Summary of Astria Therapeutics Q3 2023 Earnings Call

1. Key Financial Results and Metrics

• As of September 30, 2023, Astria Therapeutics reported $188.8 million in cash, cash equivalents, and short-term investments.
• In October 2023, the company closed a $64 million underwritten offering, which is expected to fund operations into 2026.
• The total outstanding common equivalent shares amount to 43.1 million.

2. Strategic Updates and Business Highlights

• Positive Phase 1a data for STAR-0215, aimed at treating Hereditary Angioedema (HAE), was presented at the ACAAI annual meeting, supporting its potential as a first-choice preventative treatment with dosing options of every three or six months.
• The company is expanding its pipeline with STAR-0310, an anti-OX40 antibody for atopic dermatitis, with an IND submission planned by the end of 2024 and Phase 1a initiation expected in Q1 2025.
• The ALPHA-STAR trial for STAR-0215 is progressing well, with initial proof-of-concept results expected in Q1 2024.

3. Forward Guidance and Outlook

• Astria aims to initiate a pivotal Phase III trial for STAR-0215 in Q1 2025, contingent on positive results from the ALPHA-STAR trial.
• For STAR-0310, the company plans to share preclinical data in 2024 and expects to begin a Phase 1a trial in Q1 2025.
• The company is focused on developing first-choice products that improve health outcomes for patients with allergic and immunological diseases.

4. Bad News, Challenges, or Points of Concern

• There is a competitive landscape in the treatment of HAE and atopic dermatitis, with existing therapies like Taxiro and Dupixent dominating the market.
• The company faces challenges in raising awareness among physicians and patients regarding STAR-0215, as indicated by survey results showing varying levels of familiarity.
• Payers are expected to manage the treatment class actively, which could complicate patient access to new therapies.
• The Phase 3 trial for STAR-0215 will include a placebo arm, which may slow enrollment compared to the ongoing Phase 1b trial without a placebo.

5. Notable Q&A Insights

• The accelerated timeline for the ALPHA-STAR trial's interim analysis is due to achieving target enrollment in earlier cohorts, allowing for a planned analysis sooner than expected.
• The Phase 3 trial design is anticipated to be placebo-controlled, with a similar treatment period to other trials, focusing on changes from baseline and monthly attack rates.
• There is a strong interest from both patients and healthcare providers in the three-month dosing regimen for STAR-0215, which may influence clinical development priorities.
• The company is optimistic about the potential for STAR-0310, citing a robust market opportunity in atopic dermatitis, which is currently underserved compared to psoriasis.

Overall, Astria Therapeutics is positioned for significant developments in its pipeline, but it must navigate competitive pressures and ensure effective communication with stakeholders to maximize the potential of its therapies.